Literature DB >> 9286050

Allergic mucocutaneous reactions to Japanese encephalitis vaccine.

A M Plesner1, T Rønne.   

Abstract

Japanese encephalitis (JE) vaccine has been used in childhood immunization programmes in Asia for many years. Also travellers from other parts of the world have been vaccinated before travelling in Asian countries. Recommendations for the use of JE vaccine are still debated because severe cases of adverse reactions have been reported. In Denmark an inactivated JE vaccine derived from infected mouse brain has been used and 350000 doses have been distributed from the Statens Serum Institut since 1983. In the period 1983-1995, 101 adverse reactions after JE vaccination have been registered including 73 allergic mucocutaneous reactions. These reactions have occurred each year since 1989 with frequencies varying from 1-17 per 10,000 vaccinees. The highest frequencies and the most serious reactions acquiring hospitalization were seen in the period 1989-1992. Three batches (EJN 012, 033 and 048) distributed before 1992 caused the highest number of reactions but all batches delivered in Denmark since 1989 have caused reactions. Therefore, it is still very important to collect information on adverse events as well as information of the risk of acquiring JE infection in order to give sound recommendations to travellers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286050     DOI: 10.1016/s0264-410x(97)00020-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Japanese encephalitis.

Authors:  T Solomon; N M Dung; R Kneen; M Gainsborough; D W Vaughn; V T Khanh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

2.  Report of the Workgroup on Viral Diseases.

Authors:  J Losos
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

Review 3.  Japanese viral encephalitis.

Authors:  S V Tiroumourougane; P Raghava; S Srinivasan
Journal:  Postgrad Med J       Date:  2002-04       Impact factor: 2.401

4.  A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge.

Authors:  Manisha Saini; Sudhanshu Vrati
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 5.  Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.

Authors:  Carlo Amorin Daep; Jorge L Muñoz-Jordán; Eliseo Alberto Eugenin
Journal:  J Neurovirol       Date:  2014-10-07       Impact factor: 2.643

6.  Effectiveness of the Viet Nam produced, mouse brain-derived, inactivated Japanese encephalitis vaccine in Northern Viet Nam.

Authors:  Florian Marks; Thi Thu Yen Nguyen; Nhu Duong Tran; Minh Hong Nguyen; Hai Ha Vu; Christian G Meyer; Young Ae You; Frank Konings; Wei Liu; Thomas F Wierzba; Zhi-Yi Xu
Journal:  PLoS Negl Trop Dis       Date:  2012-12-13

7.  Comparison of immune response generated against Japanese encephalitis virus envelope protein expressed by DNA vaccines under macrophage associated versus ubiquitous expression promoters.

Authors:  Mohammad Feraz Ahsan; Milind M Gore
Journal:  Virol J       Date:  2011-08-02       Impact factor: 4.099

8.  Immune-enhancing effect of nano-DNA vaccine encoding a gene of the prME protein of Japanese encephalitis virus and BALB/c mouse granulocyte-macrophage colony-stimulating factor.

Authors:  Yongzhen Zhai; Yan Zhou; Ximei Li; Guohe Feng
Journal:  Mol Med Rep       Date:  2015-03-04       Impact factor: 2.952

9.  Production of recombinant nonstructural 1 protein in Escherichia coli for early detection of Japanese encephalitis virus infection.

Authors:  Nagesh K Tripathi; Jyoti S Kumar; Karttik C Biswal; P V Lakshmana Rao
Journal:  Microb Biotechnol       Date:  2012-03-27       Impact factor: 5.813

Review 10.  Japanese encephalitis: the virus and vaccines.

Authors:  Sang-Im Yun; Young-Min Lee
Journal:  Hum Vaccin Immunother       Date:  2013-10-25       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.